hotspot -WSS

hotspot

author：fashion 2025-10-01 22:16:39 - browse：25871

BARCELONA, Spain — Some of the patients waiting in the oncology ward of a hospital here, with its green-tiled floor and white walls, had arrived for a newfangled remedy for blood cancers, what’s known as a CAR-T therapy.

The patients were not here for one of the brand-name medicines — a Kymriah or Yescarta — that have shown the power of these cell-based approaches and helped reap their makers hundreds of millions of dollars. Rather, they would be receiving a CAR-T brewed up right here at Hospital Clínic de Barcelona.

Under a special European policy, the CAR-T developed by the hospital’s experts had won regulatory approval in Spain and was reimbursed by the national health system like other authorized medications. The therapy provided another option for patients, all at a price of 89,000 euros ($97,000), roughly a third of the list prices of the CAR-T products from biopharma companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Citing H5N1 threat, CDC urges peak flu monitoring this summer

WSS

The surgeon had a dilemma only a Nazi medical text could resolve

H5N1 virus can be tracked in retail milk, scientists say

Copay coupons to count toward deductibles, after Biden court move

The surgeon had a dilemma only a Nazi medical text could resolve

Questions and answers about ramping up H5N1 bird flu vaccine

The tragedy of Johnson & Johnson’s Covid vaccine

explore

hotspot

explore

Anesthesiologist group: stop taking Ozempic before surgery

Investigation reveals sickle cell patients pressured into sterilizations

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Fentanyl is making it harder to start addiction treatment

Peter Hotez and the public health issue of online harassment

Eyeing GLP

Hepatitis C has a cure — but many Americans still lack access to it

The surgeon had a dilemma only a Nazi medical text could resolve

State Dept. review finds Biden bears some blame for Afghanistan failures

Listen: A conversation with researcher Kevin Esvelt on biosecurity

hotspot

Independent physicians launch a new lobbying group

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Parkinson’s finding may lead to tests and, someday, treatments

Questions and answers about ramping up H5N1 bird flu vaccine

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

UnitedHealth argues against case alleging wrongful AI care denials

focus

explore

hotspot

entertainment